Health
CEBINA reports positive findings on the potency of azelastine, a widely used anti-histamine, as anti-COVID-19 approach – PRNewswire
/PRNewswire/ — CEBINA GmbH, an Austrian biotech company, today announces further positive results in its collaborative COVID-19 drug repurposing project,…
VIENNA, Sept. 17, 2020 /PRNewswire/ — CEBINA GmbH, an Austrian biotech company, today announces further positive results in its collaborative COVID-19 drug repurposing project, demonstrating that a common allergy nasal spray medication containing azelastine has potent efficacy against SARS-CoV-2 in a human 3D nasal tissue model.
Azelastine, a generic anti-histamine medication, has previously been identified as a potential anti-COVID-19 drug by CEBINA in collaboration with Professor Robert Konr…
-
Noosa News13 hours agoChef Sophie Phipps prepares to open restaurant at 30-acre Alsahwa Estate
-
Business10 hours agoIs this the best ASX 200 share to buy for growth?
-
General19 hours agoThe Israel-Iran war: the moral failure of a policy of neutrality
-
General18 hours agoHow the US struck Iran’s nuclear facilities in Operation Midnight Hammer